MX2014015986A - Metodo para tratar linfoma utilizando compuestos de tienotriazolodiazepina. - Google Patents
Metodo para tratar linfoma utilizando compuestos de tienotriazolodiazepina.Info
- Publication number
- MX2014015986A MX2014015986A MX2014015986A MX2014015986A MX2014015986A MX 2014015986 A MX2014015986 A MX 2014015986A MX 2014015986 A MX2014015986 A MX 2014015986A MX 2014015986 A MX2014015986 A MX 2014015986A MX 2014015986 A MX2014015986 A MX 2014015986A
- Authority
- MX
- Mexico
- Prior art keywords
- cell
- malignant cancers
- lymphoma
- cell malignant
- treating lymphoma
- Prior art date
Links
- 206010025323 Lymphomas Diseases 0.000 title 1
- 150000001875 compounds Chemical class 0.000 title 1
- 206010028980 Neoplasm Diseases 0.000 abstract 4
- 230000003211 malignant effect Effects 0.000 abstract 4
- 210000001744 T-lymphocyte Anatomy 0.000 abstract 2
- 210000003719 b-lymphocyte Anatomy 0.000 abstract 2
- GNMUEVRJHCWKTO-FQEVSTJZSA-N 6h-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepine-6-acetamide, 4-(4-chlorophenyl)-n-(4-hydroxyphenyl)-2,3,9-trimethyl-, (6s)- Chemical compound C([C@@H]1N=C(C2=C(N3C(C)=NN=C31)SC(=C2C)C)C=1C=CC(Cl)=CC=1)C(=O)NC1=CC=C(O)C=C1 GNMUEVRJHCWKTO-FQEVSTJZSA-N 0.000 abstract 1
- 208000031671 Large B-Cell Diffuse Lymphoma Diseases 0.000 abstract 1
- 206010042971 T-cell lymphoma Diseases 0.000 abstract 1
- 208000027585 T-cell non-Hodgkin lymphoma Diseases 0.000 abstract 1
- 206010012818 diffuse large B-cell lymphoma Diseases 0.000 abstract 1
- 206010062113 splenic marginal zone lymphoma Diseases 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
- A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
- A61K31/5517—1,4-Benzodiazepines, e.g. diazepam or clozapine condensed with five-membered rings having nitrogen as a ring hetero atom, e.g. imidazobenzodiazepines, triazolam
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261663885P | 2012-06-25 | 2012-06-25 | |
| US201261670918P | 2012-07-12 | 2012-07-12 | |
| PCT/EP2013/063313 WO2014001356A1 (en) | 2012-06-25 | 2013-06-25 | Method of treating lymphoma using thienotriazolodiazepine compounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2014015986A true MX2014015986A (es) | 2016-02-11 |
Family
ID=48672651
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2014015986A MX2014015986A (es) | 2012-06-25 | 2013-06-25 | Metodo para tratar linfoma utilizando compuestos de tienotriazolodiazepina. |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20140018353A1 (enExample) |
| EP (1) | EP2863923B1 (enExample) |
| JP (1) | JP6265979B2 (enExample) |
| KR (1) | KR20150045423A (enExample) |
| CN (1) | CN105050605A (enExample) |
| AU (1) | AU2013283378B2 (enExample) |
| BR (1) | BR112014032105A2 (enExample) |
| CA (1) | CA2877434A1 (enExample) |
| IN (1) | IN2014DN11269A (enExample) |
| MX (1) | MX2014015986A (enExample) |
| RU (1) | RU2659171C2 (enExample) |
| WO (1) | WO2014001356A1 (enExample) |
Families Citing this family (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3608317A1 (en) | 2012-01-12 | 2020-02-12 | Yale University | Compounds & methods for the enhanced degradation of targeted proteins & other polypeptides by an e3 ubiquitin ligase |
| MX366703B (es) | 2013-03-15 | 2019-07-22 | Incyte Holdings Corp | Heterociclos tricíclicos como inhibidores de la proteína bet. |
| WO2015006193A1 (en) | 2013-07-08 | 2015-01-15 | Incyte Corporation | Tricyclic heterocycles as bet protein inhibitors |
| EP3027194A1 (en) * | 2013-08-01 | 2016-06-08 | Oncoethix GmbH | Pharmaceutical formulation containing thienotriazolodiazepine compounds |
| EP3030242A1 (en) * | 2013-08-06 | 2016-06-15 | Oncoethix GmbH | Method of treating diffuse large b-cell lymphoma (dlbcl) using a bet-bromodomain inhibitor |
| WO2015018520A1 (en) * | 2013-08-06 | 2015-02-12 | Oncoethix Sa | A bet-brd inhibitor represents a novel agent for alk positive anaplastic large cell lymphoma |
| WO2015018522A1 (en) * | 2013-08-06 | 2015-02-12 | Oncoethix Sa | Bet-bromodomain inhibitor shows synergism with several anti-cancer agents in pre-clinical models of diffuse large b-cell lymphoma (dlbcl) |
| US9399640B2 (en) | 2013-11-26 | 2016-07-26 | Incyte Corporation | Substituted pyrrolo[2,3-c]pyridines and pyrazolo[3,4-c]pyridines as BET protein inhibitors |
| WO2015081189A1 (en) | 2013-11-26 | 2015-06-04 | Incyte Corporation | Bicyclic heterocycles as bet protein inhibitors |
| JP2016538310A (ja) | 2013-11-27 | 2016-12-08 | オンコエシックス ゲーエムベーハー | チエノトリアゾロジアゼピン化合物を含む医薬製剤を用いる白血病の治療方法 |
| US9309246B2 (en) | 2013-12-19 | 2016-04-12 | Incyte Corporation | Tricyclic heterocycles as BET protein inhibitors |
| US20180228907A1 (en) | 2014-04-14 | 2018-08-16 | Arvinas, Inc. | Cereblon ligands and bifunctional compounds comprising the same |
| SI3674302T1 (sl) | 2014-04-23 | 2023-07-31 | Incyte Holdings Corporation | 1h-pirolo(2,3-c)piridin-7(6h)-oni in pirazolo(3,4-c)piridin-7(6h)-oni kot zaviralci proteinov bet |
| RU2016146099A (ru) | 2014-05-02 | 2018-06-05 | Онкоэтикс Гмбх | Способ лечения острого миелоидного лейкоза и/или острого лимфобластного лейкоза с помощью тиенотриазолодиазепиновых соединений |
| JP2017514907A (ja) * | 2014-05-02 | 2017-06-08 | オンコエシックス ゲーエムベーハー | チエノトリアゾロジアゼピン化合物を用いる耐性非ホジキンリンパ腫、髄芽腫及び／又はａｌｋ＋非小細胞肺癌の治療方法 |
| MX2016014574A (es) | 2014-05-08 | 2017-02-23 | Oncoethix Gmbh | El uso de compuestos de tienotriazolodiazepina para el tratamiento de cancer de mama triple-negativo. |
| AU2015273032A1 (en) | 2014-06-13 | 2016-12-15 | Oncoethix Gmbh | Method of treating non-small cell lung cancer and/or small cell lung cancer using thienotriazolodiazepine compounds |
| US9968620B2 (en) | 2014-08-19 | 2018-05-15 | Oncoethix Gmbh | Methods of treating lymphoma using thienotriazolodiazepine compounds |
| ES2855225T3 (es) | 2014-09-15 | 2021-09-23 | Incyte Corp | Heterociclos tricíclicos para su uso como inhibidores de proteínas BET |
| KR101675984B1 (ko) | 2015-02-23 | 2016-11-14 | 한양대학교 에리카산학협력단 | 티에노디아제핀 유도체 또는 이의 약학적으로 허용가능한 염, 및 이를 유효성분으로 포함하는 약학적 조성물 |
| JP7269731B2 (ja) | 2015-03-18 | 2023-05-09 | アルビナス・オペレーションズ・インコーポレイテッド | 標的タンパク質の分解向上のための化合物および方法 |
| US10683305B2 (en) | 2015-04-27 | 2020-06-16 | Concert Pharmaceuticals, Inc. | Deuterated OTX-015 |
| US10772962B2 (en) | 2015-08-19 | 2020-09-15 | Arvinas Operations, Inc. | Compounds and methods for the targeted degradation of bromodomain-containing proteins |
| US20170121347A1 (en) | 2015-10-29 | 2017-05-04 | Incyte Corporation | Amorphous solid form of a bet protein inhibitor |
| CR20190027A (es) | 2016-06-20 | 2019-05-16 | Incyte Corp | Formas sólidas cristalinas de un inhibidor de bet |
| IL312367A (en) | 2017-01-31 | 2024-06-01 | Arvinas Operations Inc | Cereblon ligands and bifunctional compounds comprising the same |
| EP3743066A4 (en) | 2018-01-26 | 2021-09-08 | Yale University | IMIDE-BASED PROTEOLYSIS MODULATORS AND RELATED METHODS OF USE |
| CN108070562A (zh) * | 2018-02-03 | 2018-05-25 | 金华市中心医院 | 一种“双打击”弥漫大b细胞淋巴瘤细胞系制备方法 |
| KR20210003804A (ko) | 2018-04-13 | 2021-01-12 | 아비나스 오퍼레이션스, 인코포레이티드 | 세레브론 리간드 및 이를 포함하는 2작용성 화합물 |
| JP7526721B2 (ja) * | 2018-09-11 | 2024-08-01 | エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト | 癌治療のためのブロモドメインＢＲＤ４阻害剤としてのｔｅｒｔ－ブチル（Ｓ）－２－（４－（フェニル）－６Ｈ－チエノ［３，２－ｆ］［１，２，４］トリアゾロ［４，３－ａ］［１，４］ジアゼピン－６－イル）アセテート誘導体及び関連化合物 |
| CN118638043A (zh) | 2019-12-19 | 2024-09-13 | 阿尔维纳斯运营股份有限公司 | 用于雄激素受体的靶向降解的化合物和方法 |
| US11833155B2 (en) | 2020-06-03 | 2023-12-05 | Incyte Corporation | Combination therapy for treatment of myeloproliferative neoplasms |
| WO2025049555A1 (en) | 2023-08-31 | 2025-03-06 | Oerth Bio Llc | Compositions and methods for targeted inhibition and degradation of proteins in an insect cell |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0661284A1 (en) | 1992-09-18 | 1995-07-05 | Yoshitomi Pharmaceutical Industries, Ltd. | Thienodiazepine compound and medicinal use thereof |
| DE69717160T2 (de) * | 1996-09-13 | 2003-05-08 | Mitsubishi Pharma Corp., Osaka | Thienotriazolodiazepinverbindungen und ihre medizinischen anwendungen |
| KR101600634B1 (ko) | 2007-12-28 | 2016-03-07 | 미쓰비시 타나베 파마 코퍼레이션 | 항암제 |
| JP5715241B2 (ja) * | 2010-05-14 | 2015-05-07 | ダナ−ファーバー キャンサー インスティテュート， インコーポレイテッド | 新生物、炎症性疾患、およびその他の障害を治療するための組成物および方法 |
| EP2902030B1 (en) * | 2010-05-14 | 2016-09-14 | Dana-Farber Cancer Institute, Inc. | Thienotriazolodiazepine compounds for treating neoplasia |
| WO2013033420A1 (en) * | 2011-08-30 | 2013-03-07 | Whitehead Institute For Biomedical Research | Methods of downregulating translocated oncogene expression using bromodomain inhibitors |
-
2013
- 2013-06-25 MX MX2014015986A patent/MX2014015986A/es unknown
- 2013-06-25 KR KR20157000782A patent/KR20150045423A/ko not_active Withdrawn
- 2013-06-25 CA CA2877434A patent/CA2877434A1/en not_active Abandoned
- 2013-06-25 EP EP13730912.6A patent/EP2863923B1/en not_active Not-in-force
- 2013-06-25 JP JP2015517810A patent/JP6265979B2/ja not_active Expired - Fee Related
- 2013-06-25 IN IN11269DEN2014 patent/IN2014DN11269A/en unknown
- 2013-06-25 AU AU2013283378A patent/AU2013283378B2/en not_active Ceased
- 2013-06-25 BR BR112014032105A patent/BR112014032105A2/pt not_active Application Discontinuation
- 2013-06-25 US US13/926,029 patent/US20140018353A1/en not_active Abandoned
- 2013-06-25 RU RU2015101106A patent/RU2659171C2/ru not_active IP Right Cessation
- 2013-06-25 WO PCT/EP2013/063313 patent/WO2014001356A1/en not_active Ceased
- 2013-06-25 CN CN201380045846.0A patent/CN105050605A/zh active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CA2877434A1 (en) | 2014-01-03 |
| BR112014032105A2 (pt) | 2017-08-01 |
| AU2013283378B2 (en) | 2017-07-13 |
| JP6265979B2 (ja) | 2018-01-24 |
| IN2014DN11269A (enExample) | 2015-10-09 |
| AU2013283378A1 (en) | 2015-01-29 |
| RU2015101106A (ru) | 2016-08-10 |
| CN105050605A (zh) | 2015-11-11 |
| EP2863923A1 (en) | 2015-04-29 |
| US20140018353A1 (en) | 2014-01-16 |
| RU2659171C2 (ru) | 2018-06-28 |
| EP2863923B1 (en) | 2019-05-08 |
| JP2015531747A (ja) | 2015-11-05 |
| KR20150045423A (ko) | 2015-04-28 |
| WO2014001356A1 (en) | 2014-01-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2014015986A (es) | Metodo para tratar linfoma utilizando compuestos de tienotriazolodiazepina. | |
| MX370814B (es) | Pirazolo[3,4-d]pirimidinas sustituidas y usos de las mismas. | |
| GEP201706786B (en) | Methods and drug products for treating alzheimer's disease | |
| MX2013010770A (es) | Tratamiento de tumores solidos. | |
| CL2012003604A1 (es) | Compuestos heterociclicos derivados de piridina carboxamida sustituida; proceso de preparacion; composicion farmaceutica; combinacion farmaceutica; uso en el tratamiento de trastornos proliferativos celulares, enfermedad de parkinson, cancer, entre otros. | |
| NZ754827A (en) | Substituted pyrazole compounds and methods of using them for treatment of hyperproliferative diseases | |
| PH12013502565A1 (en) | Substituted imidazopyridinyl-aminopyridine compounds | |
| NZ726488A (en) | Compositions and methods for transmucosal absorption | |
| PH12016502354A1 (en) | Pharmaceutical composition | |
| GEP201706624B (en) | Triazolopyrazine as brd4 inhibitors and usage thereof for cancer treatment | |
| MX2010003815A (es) | Terapia de combinacion de un anticuerpo anti-cd20 de tipo ii con un agente activo anti-bcl-2. | |
| MX351166B (es) | Compuestos terapéuticamente activos y sus métodos de uso. | |
| MX350432B (es) | Compuestos terapeuticamente activos y sus metodos de empleo. | |
| MX365525B (es) | Compuestos que regulan la expresión de subunidades alfa de canales de sodio regulados por voltaje en enfermedades relacionadas con epilepsia mioclónica severa de la infancia. | |
| MX347765B (es) | Inhibidores macrociclicos de la quinasa flt3. | |
| MY172308A (en) | Bicyclic pyrazinone derivatives | |
| MX362939B (es) | Derivados de (aza-)isoquinolinona. | |
| MX2014012477A (es) | Inhibidores pirrolopirazona de tanquirasa. | |
| TN2012000610A1 (en) | Heterocyclic compounds, their preparation and their therapeutic application | |
| MD4538B1 (ro) | 1-Piperazino-3-fenil-indani deuteraţi pentru tratamentul schizofreniei | |
| MX360409B (es) | Terapia de combinacion de dosis fija para la enfermedad de parkinson. | |
| MX2014014816A (es) | Composicion farmaceutica para tratar inflamacion y dolor. | |
| MX2013006184A (es) | Compuestos de oxazol [5, 4-b]piridin-5-ilo y su uso para el tratamiento de cancer. | |
| PH12015501980A1 (en) | Pyrroloquinolinyl-pyrrolidine-2,5-dione formulations and methods for preparing and using same | |
| WO2012125871A3 (en) | Aconitine compounds, compositions, uses, and preparation thereof |